Secondary resistance with tumor progression within the first 2 years of treatment remains a significant clinical problem, affecting 40% to 50% of patients under TKI treatment for metastatic GISTs, usually due to resistance mutations occurring in either KIT or PDGFRA (5, 15, 16). This evidence concerns the gene PDGFRA and neoplasm.